Rapid Therapeutic Science Laboratories, Inc. - FORM 10-K/A - EX-31.2 - CERTIFICATION - August 26, 2020

Attached files

file filename
EX-31.1 - CERTIFICATION - Rapid Therapeutic Science Laboratories, Inc.rtsl_ex311.htm
EX-21.1 - SUBSIDIARIES OF THE REGISTRANT - Rapid Therapeutic Science Laboratories, Inc.rtsl_ex211.htm
EX-10.4 - FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT DATED JUNE 25, 2020 BY AND BETWEE - Rapid Therapeutic Science Laboratories, Inc.rtsl_ex104.htm
EX-10.1 - RAPID THERAPEUTIC SCIENCE LABORATORIES, INC. 2018 STOCK PLAN - Rapid Therapeutic Science Laboratories, Inc.rtsl_ex101.htm
EX-4.1 - DESCRIPTION OF SECURITIES OF THE REGISTRANT - Rapid Therapeutic Science Laboratories, Inc.rtsl_ex41.htm
10-K/A - 10-K/A - Rapid Therapeutic Science Laboratories, Inc.rtsl_10ka.htm

Exhibit 31.2

 

CERTIFICATION PURSUANT TO

15 U.S.C. SECTION 7241 AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, D. Hughes Watler, Jr., certify that:

 

1.I have reviewed this annual report on Form 10-K/A of Rapid Therapeutic Science Laboratories, Inc. (the “registrant”); and 

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. 

 

Date:  August 26, 2020

 

/s/ D. Hughes Watler, Jr.

D. Hughes Watler, Jr.

Chief Financial Officer

(Principal Financial Officer)

 

 

 

 

 

 

 

 

Rapid Therapeutic Science Laboratories, Inc. Reports